8-K: Candel Therapeutics Reports Strong Q2, Advances CAN-2409

Candel Therapeutics announced its second quarter 2025 financial results and provided key updates on its clinical programs, including significant progress for CAN-2409 in prostate cancer.

Summary

• Reported second quarter 2025 financial results.
• Presented positive Phase 3 results for CAN-2409 in localized prostate cancer at the 2025 ASCO Annual Meeting, demonstrating a statistically significant 30% improvement in disease-free survival (HR 0.70, p=0.0155) compared to placebo.
• Received FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for CAN-2409 for the treatment of prostate cancer.
• Received Orphan Designation for CAN-2409 for the treatment of pancreatic cancer from the European Medicines Agency (EMA).
• Cash and cash equivalents totaled $100.7 million as of June 30, 2025, projected to fund operations into Q1 2027.
• Net loss for Q2 2025 was $4.8 million, a substantial decrease from $22.2 million in Q2 2024, primarily due to a favorable change in the fair value of warrant liability.
• Completed a registered direct offering in June 2025, raising approximately $15 million in gross proceeds from the sale of 3.2 million shares at $4.67 per share.
• Appointed Charles Schoch as Chief Financial Officer and Maha Radhakrishnan, M.D., to the Board of Directors in June 2025.
• Anticipates Biologics License Application (BLA) submission for CAN-2409 in intermediate-to-high-risk localized prostate cancer in Q4 2026.

Sentiment

Score: 9

Explanation: The filing reports highly positive clinical trial results for CAN-2409 across multiple indications, including a pivotal Phase 3 success in prostate cancer, leading to FDA RMAT designation. Financials show a significantly reduced net loss and an extended cash runway, bolstered by a recent capital raise. These factors indicate strong progress and a positive outlook for the company's lead therapeutic candidate.

Positives

• Positive Phase 3 results for CAN-2409 in localized prostate cancer, meeting the primary endpoint with a 30% improvement in disease-free survival (HR 0.70, p=0.0155).
• FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for CAN-2409 in prostate cancer, indicating potential for expedited development and review.
• EMA Orphan Designation for CAN-2409 in pancreatic cancer.
• Positive overall survival data from Phase 2a clinical trial of CAN-2409 in NSCLC, with median overall survival of 24.5 months (21.5 months for progressive disease patients), significantly longer than published literature (9.8-11.8 months).
• Positive overall survival data from Phase 2a clinical trial of CAN-2409 in borderline resectable PDAC, with median overall survival of 31.4 months versus 12.5 months in the control arm.
• Cash and cash equivalents of $100.7 million as of June 30, 2025, expected to fund operations into Q1 2027.
• Significant reduction in net loss to $4.8 million in Q2 2025 from $22.2 million in Q2 2024, primarily due to a favorable change in the fair value of warrant liability.
• Successful completion of a registered direct offering, raising $15 million to support pre-commercialization and launch readiness.
• Strengthening of management and board with the appointment of Charles Schoch as CFO and Dr. Maha Radhakrishnan to the Board of Directors.

Negatives

• Research and development expenses increased to $7.0 million in Q2 2025 from $5.0 million in Q2 2024, primarily due to increased manufacturing costs.
• General and administrative expenses increased to $4.2 million in Q2 2025 from $3.6 million in Q2 2024, due to commercial readiness costs and higher professional and consulting fees.
• Cash and cash equivalents decreased slightly from $102.7 million as of December 31, 2024, to $100.7 million as of June 30, 2025.

Risks

• Final data from preclinical studies and completed clinical trials may differ materially from reported interim data from ongoing studies and trials.
• Ability to efficiently discover and develop product candidates.
• Ability to obtain and maintain regulatory approval of product candidates.
• Ability to maintain intellectual property.
• Risks related to the implementation of the business model, including strategic plans.
• Other risks identified in SEC filings, including the most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q.

Future Outlook

Candel Therapeutics anticipates submitting the Biologics License Application (BLA) for CAN-2409 in intermediate-to-high-risk localized prostate cancer to the FDA in Q4 2026. The company also expects to release additional clinical and biomarker activity data from an ongoing Phase 1b clinical trial evaluating repeat doses of CAN-3110 in recurrent high-grade glioma (rHGG) in Q4 2025 and plans to host a virtual Research and Development event in Q4 2025. Existing cash and cash equivalents are projected to fund operations into Q1 2027.

Management Comments

• "This quarter marked several pivotal achievements for Candel, highlighted by the FDA RMAT Designation for CAN-2409, and being selected for an oral presentation at ASCO, reflecting the strength of the data based on our pivotal phase 3 clinical trial in localized prostate cancer."
• "Further, the addition of Dr. Maha Radhakrishnan to our Board of Directors, as well as the appointment of Charles Schoch as Chief Financial Officer, further strengthens our organization as we accelerate our pre-commercialization activities and advance toward BLA submission, anticipated in Q4 2026."
• "The positive results from our clinical trials in prostate cancer, pancreatic cancer, and non-small cell lung cancer reinforce the therapeutic potential of CAN-2409 as a novel therapy."
• "With the proceeds from our recent registered direct offering being utilized to support pre-commercialization and launch readiness activities, and with multiple regulatory designations, we believe we are well-positioned to execute on our near-term milestones and advance toward our goal of bringing this important treatment option to patients with prostate cancer."

Industry Context

Candel Therapeutics operates in the highly competitive and innovative field of oncology, specifically focusing on multimodal biological immunotherapies. The positive Phase 3 results for CAN-2409 in prostate cancer, coupled with FDA RMAT designation, position the company as a potential leader in novel prostate cancer treatments, a significant market. The promising data in NSCLC and pancreatic cancer also indicate broad applicability of their platform, potentially addressing areas with high unmet medical needs where current standard-of-care treatments offer limited survival benefits. The company's focus on in situ immunization and systemic anti-tumor immune response aligns with the broader industry trend towards leveraging the body's own immune system to fight cancer, moving beyond traditional chemotherapy and radiation.

Comparison to Industry Standards

• CAN-2409's median overall survival of 21.5 months in NSCLC patients with progressive disease despite ICI treatment is markedly longer than the 9.8-11.8 months of survival reported in published literature for the same patient population receiving standard of care docetaxel chemotherapy (Paz-Ares LG et al. J Clin Oncol 2024;42:2860-2872; Ahn MJ et al. J Clin Onc 2024;43:260-272).
• In borderline resectable PDAC, CAN-2409 and chemoradiotherapy achieved a median overall survival of 31.4 months, significantly exceeding the 12.5 months observed in the control arm treated with chemoradiotherapy.
• The 30% improvement in disease-free survival for CAN-2409 in localized prostate cancer, with a Hazard Ratio of 0.70 and p-value of 0.0155, represents a clinically meaningful outcome in a pivotal Phase 3 trial conducted under an FDA Special Protocol Assessment.

Management Changes

Stakeholder Impact

• Shareholders: Potential positive impact due to strong clinical data, regulatory designations, extended cash runway, and progress towards BLA submission, which could lead to increased share value. Dilution from the recent offering is a factor, but offset by the use of proceeds for pre-commercialization.
• Patients: Significant positive impact, as CAN-2409 shows potential as a novel, effective treatment option for prostate cancer, NSCLC, and pancreatic cancer, addressing high unmet medical needs.
• Employees: Positive impact due to company growth, advancement of pipeline, and strengthening of the leadership team, indicating stability and future opportunities.
• Creditors: Positive impact due to improved financial stability and extended cash runway.

Next Steps

• Additional clinical and biomarker activity data from an ongoing Phase 1b clinical trial evaluating repeat doses of CAN-3110 in recurrent high-grade glioma (rHGG) expected in Q4 2025.
• Host a virtual Research and Development event in Q4 2025.
• Submission of Biologics License Application (BLA) for CAN-2409 in prostate cancer expected in Q4 2026.
• Pre-BLA readiness activities, including Chemistry, Manufacturing, and Controls (CMC) and preparation of clinical study reports.
• Utilize proceeds from recent offering to support pre-commercialization and launch readiness activities.

Key Dates

Recommendation

Candel Therapeutics has reported exceptionally strong clinical data for its lead candidate, CAN-2409, across multiple difficult-to-treat cancers, including a pivotal Phase 3 success in prostate cancer that met its primary endpoint. The receipt of FDA RMAT designation for prostate cancer and EMA Orphan designation for pancreatic cancer significantly de-risks the regulatory pathway and highlights the potential for expedited approval. The company's financial position has improved with a significantly reduced net loss and an extended cash runway into Q1 2027, supported by a recent capital raise. The clear path to BLA submission in Q4 2026 for prostate cancer, combined with promising results in NSCLC and pancreatic cancer, suggests substantial future value creation. The strengthening of the management team further supports execution. These factors collectively indicate a compelling investment opportunity.

Keywords

Candel Therapeutics, CADL, biopharmaceutical, immunotherapy, cancer treatment, CAN-2409, prostate cancer, NSCLC, pancreatic cancer, clinical trials, FDA RMAT, Orphan Designation, BLA submission, financial results, Q2 2025, oncology, gene therapy, oncolytic virus, CAN-3110, high-grade glioma, registered direct offering